symbol,statement_type,period_end,line_item,value
AARTIPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.244766
AARTIPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,4744899000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,869040000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,11278775000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,EBITDA,4744899000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,EBIT,3875859000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-268964000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,268964000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,17376079000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,90680692.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,90620359.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,30.04
AARTIPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,30.06
AARTIPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Minority Interests,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,2724048000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,882847000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,3606895000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,101192000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Write Off,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-268964000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,268964000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Operating Income,3774666000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,6097304000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,3608669000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,869040000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Amortization,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,869040000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Research And Development,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
AARTIPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
AARTIPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,9871970000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,11278775000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,21150745000.0
AARTIPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,21150745000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.278177
AARTIPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,3909419000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,12230000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,12230000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,732353000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,10207173000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,EBITDA,3909419000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,EBIT,3177066000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-172147000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,172147000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Interest Income,30419000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,15397977000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,11593000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,90640201.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,90640201.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,23.93
AARTIPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,23.93
AARTIPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Minority Interests,
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,2169020000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,835899000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,3004919000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,48950000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,190000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,-190000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Write Off,
AARTIPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-172147000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,
AARTIPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,172147000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,30419000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Operating Income,3128116000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,5190804000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,3074377000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,732353000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Amortization,12700000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,732353000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Research And Development,83701000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,803586000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,679712000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,123874000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,11593000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,8318920000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,10207173000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,18526093000.0
AARTIPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,18526093000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,210274.380423
AARTIPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.258005
AARTIPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,3442877000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,815000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,815000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1934934000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,625427000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,12539679000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,EBITDA,3443692000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,EBIT,2818265000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,-201144000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,210517000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Interest Income,9373000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,1934329274.380423
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1934934000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,16564957000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,39964000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,90626008.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,90626008.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,21.35
AARTIPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,21.35
AARTIPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,1934934000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,1934934000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income,1934934000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Minority Interests,0.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,1934935000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,1934935000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,672813000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,2607748000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,493000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,-580000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,580000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Write Off,59000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-201144000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,14185000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,210517000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,9373000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Operating Income,2795088000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,4025278000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,813797000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,625427000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Amortization,443000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,624984000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Research And Development,139605000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,881930000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,737537000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,144393000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,39964000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,6820366000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,12539679000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,19360045000.0
AARTIPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,19360045000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,29423.552778
AARTIPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.213214
AARTIPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,1978253000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,138000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,138000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,421186000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,8796993000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,EBITDA,1978391000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,EBIT,1557205000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,-119530000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,3401000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Interest Income,57000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,1222402423.552778
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,10268713000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,1151000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,90626008.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,90626008.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,13.489627
AARTIPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,13.489627
AARTIPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Minority Interests,
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,1222511000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,331293000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,1553804000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,-3213000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,138000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,-208000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Write Off,70000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-119530000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,116186000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,3401000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,57000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Operating Income,1651623000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,1471720000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,644350.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,421186000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Amortization,
AARTIPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,421186000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Research And Development,
AARTIPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,276448000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,261364000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,15084000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,1151000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,3123343000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,8796993000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,11920336000.0
AARTIPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,11920336000.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
AARTIPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
AARTIPHARM.NS,income,2021-03-31 00:00:00,EBIT,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Interest Income,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Minority Interests,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Write Off,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Amortization,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Research And Development,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,46000.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,46000.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,0.0
AARTIPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
AARTIPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
